Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct 24;4(1):39-42.
doi: 10.1002/iju5.12233. eCollection 2021 Jan.

False-positive 123I-metaiodobenzylguanidine scan in a patient with renal cell carcinoma: A case of chromophobe renal cell carcinoma oncocytic variant with a complicated clinical course

Affiliations
Case Reports

False-positive 123I-metaiodobenzylguanidine scan in a patient with renal cell carcinoma: A case of chromophobe renal cell carcinoma oncocytic variant with a complicated clinical course

Takahito Suyama et al. IJU Case Rep. .

Abstract

Introduction: 123I-metaiodobenzylguanidine scanning has high sensitivity and specificity for the diagnosis of tumors derived from sympathetic nerves or the adrenal medulla. We report the rare case of a 123I-metaiodobenzylguanidine false-positive renal cell carcinoma.

Case presentation: The patient was referred to our hospital with an incidental left renal mass during evaluation for hypertension. An ovarian tumor and prominent ascites were also observed. Serum and urine catecholamine levels were high to suspect a catecholamine-producing tumor of the kidney. 123I-metaiodobenzylguanidine scintigraphy showed increased 123I-metaiodobenzylguanidine intake in the tumor. Laparoscopic radical left nephrectomy was performed. The pathologic diagnosis was an oncocytic variant of chromophobe renal cell carcinoma. No pheochromocytoma features were found.

Conclusion: We report the first case of a 123I-metaiodobenzylguanidine false-positive renal cell carcinoma. This case was diagnosed with primary aldosteronism and Meigs' syndrome, which made the clinical course more complicated.

Keywords: 123I‐MIBG false‐positive; Meigs’ syndrome; chromophobe RCC; oncocytic variant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
CT image. Arrow: left kidney tumor with internal degeneration. *Ascites.
Fig. 2
Fig. 2
123I‐MIBG scintigraphy. 123I‐MIBG intake is increased in the left kidney tumor.
Fig. 3
Fig. 3
Microscopy, HE staining and immunohistochemistry. Eosinophilic cells with abundant granular cytoplasm are seen growing in a tubular and/or sheetlike structure. The tumor was positive for CK7 and colloidal iron.
Fig. 4
Fig. 4
Electron microscopy. Abundant mitochondria are observed in the cytoplasm.

Similar articles

Cited by

References

    1. Beierwaltes WH. Update on basic research and clinical experience with metaiodobenzylguanidine. Med. Pediatr. Oncol. 1987; 15: 163–9. - PubMed
    1. Takasu N, Hayashi M, Takara M et al False‐positive 123I‐metaiodobenzylguanidine (MIBG) scan in a patient with angiomyolipoma; positive MIBG scan does not necessarily indicate the presence of pheochromocytoma. Intern. Med. 2007; 46: 1717–21. - PubMed
    1. Inoue Y, Akahane M, Kitazawa T et al False positive uptake of metaiodobenzylguanidine in hepatocellular carcinoma. Br. J. Radiol. 2002; 75: 548–51. - PubMed
    1. Granata C, Carlini C, Conte M, Claudiani F, Campus R, Rizzo A. False positive MIBG scan due to accessory spleen. Med. Pediatr. Oncol. 2001; 37: 138–9. - PubMed
    1. Rainis T, Ben‐Haim S, Dickstein G. False positive metaiodobenzylguanidine scan in a patient with a huge adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2000; 85: 5–7. - PubMed

Publication types